Abstract: The invention provides new methods of treatment using TGF-?3 to inhibit scarring in humans, and TGF-?3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment each centimetre of wound margin, or each centimetre of a site at which a wound is to be formed, is provided with between approximately 350 ng and 1000 ng of TGF-?3; and in a second incidence of treatment, occurring after a wound is formed, and between 8 and 48 hours after the first incidence of treatment, the wound is provided with an amount of between approximately 350 ng and 1000 ng of TGF-?3 per centimetre of wound margin in which scarring is to be inhibited. The amount of TGF-?3 provided may be the same in each incidence of treatment. The amount of TGF-?3 provided per centimetre in each incidence of treatment may preferably be approximately 500 ng. The TGF-?3 may be provided by intradermal injection.

Abstract: A method and apparatus for determining the efficacy of a medicament for the treatment of wounds or scars. The method comprises selecting first and second scarring site portions wherein said first scarring site portion has been treated with said medicament. A pair of images comprising a first image of said first scarring site portion and a second image of said second scarring site portion is generated, and the pair of images is displayed. A recording element comprising first and second recording portions is provided, wherein said first recording portion comprises a plurality of first points indicating that scarring in said first image is less severe than scarring in said second image, and said second recording portion comprises a plurality of second points indicating that scarring in said second image is less severe than scarring in said first image, each of said first and second points having different associated values.